Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer

• Published in: Cancers Vol. 15; no. 8; p. 2236
• Main Authors: Somanath, Payaningal R, Chernoff, Jonathan, Cummings, Brian S, Prasad, Sandip M, Homan, Harvey D
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11-04-2023; MDPI
• Subjects: Actin; Allosteric properties; Antigens; Antimitotic agents; Antineoplastic agents; Brain research; Cancer; Cancer therapies; Care and treatment; Cell activation; Cell cycle; Cell survival; Clinical trials; Cytology; Development and progression; Drug approval; Drug targeting; Drug therapy; Epithelial cells; Extracellular matrix; FDA approval; Health aspects; Heart; Kinases; Medical prognosis; Metastases; Metastasis; Methods; Molecular modelling; Mortality; Motility; Nervous system diseases; Neurological diseases; p21-activated kinase; Pathophysiology; Phosphotransferases; Physiological aspects; Prostate cancer; Proteins; Radiation therapy; Review; Therapeutic applications; Transforming growth factors; United States; United States > US; SSL-IPA-3; PAK1; prostate cancer; metastasis; therapy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15082236

Metastatic prostate cancer (mPCa) has limited therapeutic options and a high mortality rate. The p21-activated kinase (PAK) family of proteins is important in cell survival, proliferation, and motility in physiology, and pathologies such as infectious, inflammatory, vascular, and neurological diseases as well as cancers. Group-I PAKs (PAK1, PAK2, and PAK3) are involved in the regulation of actin dynamics and thus are integral for cell morphology, adhesion to the extracellular matrix, and cell motility. They also play prominent roles in cell survival and proliferation. These properties make group-I PAKs a potentially important target for cancer therapy. In contrast to normal prostate and prostatic epithelial cells, group-I PAKs are highly expressed in mPCA and PCa tissue. Importantly, the expression of group-I PAKs is proportional to the Gleason score of the patients. While several compounds have been identified that target group-I PAKs and these are active in cells and mice, and while some inhibitors have entered human trials, as of yet, none have been FDA-approved. Probable reasons for this lack of translation include issues related to selectivity, specificity, stability, and efficacy resulting in side effects and/or lack of efficacy. In the current review, we describe the pathophysiology and current treatment guidelines of PCa, present group-I PAKs as a potential druggable target to treat mPCa patients, and discuss the various ATP-competitive and allosteric inhibitors of PAKs. We also discuss the development and testing of a nanotechnology-based therapeutic formulation of group-I PAK inhibitors and its significant potential advantages as a novel, selective, stable, and efficacious mPCa therapeutic over other PCa therapeutics in the pipeline.